<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="7837"><DrugName>OSU-6162</DrugName><DrugSynonyms><Name><Value>(-)-DS 121</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PNU-96391A</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>(-)-OSU-6162</Value></Name><Name><Value>OSU-6162</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PNU-9639</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>146798-66-5</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="25752">University of Gothenburg</CompanyOriginator><CompaniesPrimary><Company id="25752">University of Gothenburg</Company><Company id="21110">Karolinska Institutet</Company></CompaniesPrimary><CompaniesSecondary><Company id="22006">Pharmacia &amp; Upjohn Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="7837" type="Drug"><TargetEntity id="191573" type="siDrug">(-)-DS-121</TargetEntity></SourceEntity><SourceEntity id="21110" type="Company"><TargetEntity id="5035523906" type="organizationId">Karolinska Institutet</TargetEntity></SourceEntity><SourceEntity id="22006" type="Company"><TargetEntity id="5036162624" type="organizationId">Pharmacia &amp; Upjohn LLC</TargetEntity></SourceEntity><SourceEntity id="25752" type="Company"><TargetEntity id="5000689242" type="organizationId">University of Gothenburg</TargetEntity></SourceEntity><SourceEntity id="11" type="ciIndication"><TargetEntity id="F10.2" type="ICD10"/><TargetEntity id="10001639" type="MEDDRA"/><TargetEntity id="D000437" type="MeSH"/><TargetEntity id="-1679518733" type="omicsDisease"/><TargetEntity id="1119" type="siCondition"/></SourceEntity><SourceEntity id="170" type="ciIndication"><TargetEntity id="G10" type="ICD10"/><TargetEntity id="10020469" type="MEDDRA"/><TargetEntity id="D006816" type="MeSH"/><TargetEntity id="399" type="ORPHANET"/><TargetEntity id="-682751376" type="omicsDisease"/><TargetEntity id="126" type="siCondition"/></SourceEntity><SourceEntity id="282" type="ciIndication"><TargetEntity id="10061920" type="MEDDRA"/><TargetEntity id="D011618" type="MeSH"/><TargetEntity id="61" type="siCondition"/></SourceEntity><SourceEntity id="299" type="ciIndication"><TargetEntity id="F20" type="ICD10"/><TargetEntity id="10039626" type="MEDDRA"/><TargetEntity id="D012559" type="MeSH"/><TargetEntity id="-729613619" type="omicsDisease"/><TargetEntity id="65" type="siCondition"/></SourceEntity><SourceEntity id="588" type="ciIndication"><TargetEntity id="10013663" type="MEDDRA"/><TargetEntity id="D019966" type="MeSH"/><TargetEntity id="-1673270541" type="omicsDisease"/><TargetEntity id="1118" type="siCondition"/></SourceEntity><SourceEntity id="748" type="ciIndication"><TargetEntity id="10022116" type="MEDDRA"/><TargetEntity id="1239" type="siCondition"/><TargetEntity id="1186" type="siCondition"/></SourceEntity><SourceEntity id="829" type="ciIndication"><TargetEntity id="10016256" type="MEDDRA"/><TargetEntity id="D005221" type="MeSH"/><TargetEntity id="-961418346" type="omicsDisease"/><TargetEntity id="2620" type="siCondition"/></SourceEntity><SourceEntity id="93" type="ciIndication"><TargetEntity id="10012378" type="MEDDRA"/><TargetEntity id="D003863" type="MeSH"/><TargetEntity id="-508468160" type="omicsDisease"/><TargetEntity id="53" type="siCondition"/></SourceEntity><SourceEntity id="150" type="Action"><TargetEntity id="125" type="Mechanism">Dopamine D2 Antagonists</TargetEntity></SourceEntity><SourceEntity id="1191" type="Action"><TargetEntity id="126" type="Mechanism">Dopamine D3 Antagonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00633" type="ciTarget"><TargetEntity id="80088336218133" type="siTarget">D(2) dopamine receptor</TargetEntity><TargetEntity id="8168" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-00634" type="ciTarget"><TargetEntity id="5001063318143" type="siTarget">D(3) dopamine receptor</TargetEntity><TargetEntity id="8034" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="C2">Phase 2 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="11">Alcoholism</Indication><Indication id="829">Fatigue</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="170">Huntingtons chorea</Indication><Indication id="282">Psychotic disorder</Indication><Indication id="299">Schizophrenia</Indication><Indication id="588">Drug dependence</Indication><Indication id="748">Injury</Indication><Indication id="93">Depression</Indication></IndicationsSecondary><ActionsPrimary><Action id="1191">Dopamine D3 receptor antagonist</Action><Action id="150">Dopamine D2 receptor antagonist</Action><Action id="1622">Dopamine autoreceptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2941">Antidepressant</Action><Action id="2943">Antipsychotic</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N6A</Code><Name>ANTI-DEPRESSANTS AND MOOD STABILISERS</Name></Ephmra><Ephmra><Code>N5A</Code><Name>ANTIPSYCHOTICS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-10-01T07:16:44.000Z</LastModificationDate><ChangeDateLast>2018-10-01T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="18937" linkType="Company"&gt;&lt;/ulink&gt;&lt;ulink linkID="25752" linkType="Company"&gt;University of Gothenburg&lt;/ulink&gt; is developing OSU-6162 (PNU-96391A; PNU-9639), a dopamine D2/D3 receptor antagonist, as a potential therapy, for head trauma and mental fatigue [&lt;ulink linkID="1311572" linkType="Reference"&gt;1311572&lt;/ulink&gt;]. The University, in collaboration with &lt;ulink linkID="18937" linkType="Company"&gt;&lt;/ulink&gt;&lt;ulink linkID="25752" linkType="Company"&gt;&lt;/ulink&gt;&lt;ulink linkID="21110" linkType="Company"&gt;Karolinska Institute&lt;/ulink&gt;, is also developing the drug for the potential treatment of alcohol dependence  [&lt;ulink linkID="1311572" linkType="Reference"&gt;1311572&lt;/ulink&gt;]. In September 2017, a phase II study was initiated for fatigue  [&lt;ulink linkID="1955107" linkType="Reference"&gt;1955107&lt;/ulink&gt;]. In October 2015, results from a phase II exploratory human laboratory study were published [&lt;ulink linkID="1703094" linkType="Reference"&gt;1703094&lt;/ulink&gt;], [&lt;ulink linkID="1703273" linkType="Reference"&gt;1703273&lt;/ulink&gt;]; in September 2017, secondary analysis data were presented [&lt;ulink linkID="1964897" linkType="Reference"&gt;1964897&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="18937" linkType="Company"&gt;Pharmacia&lt;/ulink&gt; (formerly &lt;ulink linkID="18995" linkType="Company"&gt;Pharmacia &amp;amp; Upjohn&lt;/ulink&gt;) was investigating the drug for  depression, psychosis, schizophrenia and substance dependence [&lt;ulink linkID="271419" linkType="reference"&gt;271419&lt;/ulink&gt;], [&lt;ulink linkID="160528" linkType="reference"&gt;160528&lt;/ulink&gt;]. As of 1999, &lt;ulink linkID="7837" linkType="Drug"&gt;PNU-96391A&lt;/ulink&gt; (structure shown) had been under evaluation in a patient with Huntington's disease [&lt;ulink linkID="483151" linkType="reference"&gt;483151&lt;/ulink&gt;]. In March 2002, &lt;ulink linkID="7837" linkType="Drug"&gt;PNU-96391A&lt;/ulink&gt; was reported to have completed phase II trials before it was discontinued [&lt;ulink linkID="444997" linkType="reference"&gt;444997&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;University of Gothenburg was previously developing OSU-6162, for the potential treatment of head trauma and mental fatigue  [&lt;ulink linkID="1311572" linkType="Reference"&gt;1311572&lt;/ulink&gt;]. In July 2012, the drug was in clinical development for head trauma and mental fatigue  [&lt;ulink linkID="1311572" linkType="Reference"&gt;1311572&lt;/ulink&gt;]. However, no further development had been reported since then.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In June 2017, a phase II double-blind, randomised, placebo-controlled study (&lt;ulink linkID="304689" linkType="Protocol"&gt;NCT03209830&lt;/ulink&gt;; 2016/2214) of OSU-6162 for the treatment of patients (expected n = 100) with fatigue and other neuropsychological sequelae after aneurysmal subarachnoid hemorrhage was to begin in September 2017 in Norway; at that time, the study was expected to be completed in November 2019 [&lt;ulink linkID="1955107" linkType="Reference"&gt;1955107&lt;/ulink&gt;]. In September 2017, the trial was initiated [&lt;ulink linkID="1955107" linkType="Reference"&gt;1955107&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In October 2015, results from a phase II exploratory human laboratory study to assess the effects of OSU-6162 on cue- and priming-induced craving in alcohol dependent individuals (n = 56) were published. The individuals were randomized for 14-day treatment period of OSU-6162 or placebo after their baseline impulsivity levels and subjective ratings of alcohol craving were assessed using the shortened version of the Desire for Alcohol Questionnaire and visual analogue scales (VAS).  Data demonstrated that, no significant effect on cue-induced alcohol craving, but significantly reduced  priming-induced craving at day-15. Also, subjective disliking of alcohol in drug treated inidividuals were observed. OSU-6162 was found to be safe and well tolerated [&lt;ulink linkID="1703094" linkType="Reference"&gt;1703094&lt;/ulink&gt;], [&lt;ulink linkID="1703273" linkType="Reference"&gt;1703273&lt;/ulink&gt;]. In September 2017, secondary analysis data were presented at the 30th ECNP Congress in Paris, France. Treatment with (-)-OSU-6162 exhibited an improvement in Stockings of Cambridge task (SOC) number of problems solved in minimum moves versus placebo (0.80 versus 0.00; p = 0.012), while improvement was not observed for mean number of moves for the five-move-problems (-1.0 versus -0.27; p = 0.120). Treatment with (-)-OSU-6162 did not have any significant effect on changes in main outcomes on Stop Signal Task (stop signal reaction time [SSRT] and proportion of successful stops), Cambridge Gambling Task (overall proportion bet, risk taking), Spatial Working Memory task (between-errors, within-errors, strategy), Rapid Visual Information task (total misses, correct rejections) or Emotion Recognition task (percent correct) [&lt;ulink linkID="1964897" linkType="Reference"&gt;1964897&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2012, enrollment in a clinical study was expected to initiate during the autumn of 2012 for alcohol dependence [&lt;ulink linkID="1311572" linkType="Reference"&gt;1311572&lt;/ulink&gt;]. In  May 2014, data from this double-blind, placebo-controlled, outpatient study were presented at the 167th Annual Meeting of the APA in New York, NY. When compared with placebo, (-)-OSU-6162 significantly attenuated craving immediately after intake of an alcoholic drink. (-)-OSU-6162 showed no effect on cue-induced craving [&lt;ulink linkID="1553931" linkType="Reference"&gt;1553931&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In October 2015, preclinical data were published.  The study was to investigate the effects of long-term drinking and OSU-6162 treatment  at a dose of sc 30 mg/kg on basal and alcohol-induced  nucleus accumbens dopamine outputs in wistar rats after 10  months of intermittent access to 20% alcohol.   Data demonstrated that, the basal and alcohol-induced  nucleus accumbens  dopamine outputs were significantly lower in long-term drinking rats  compared with alcohol-naive rats.In the long-term drinking rats, OSU-6162 slowly increased and maintained the dopamine output significantly raised compared with baseline for at least 4 h. No conditioned place preference (CPP) in either long-term drinking or alcohol-naive rats was found. Also,  the pre-treatment had no blunt ethanol-induced dopamine output in nucleus accumbens of ethanol-naive rats [&lt;ulink linkID="1703094" linkType="Reference"&gt;1703094&lt;/ulink&gt;], [&lt;ulink linkID="1703323" linkType="Reference"&gt;1703323&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2012, preclinical studies had demonstrated that the drug blocked  the increase in dopamine levels in a rat model.  OSU-6162 attenuated several ethanol-mediated behaviors, including voluntary ethanol consumption, ethanol withdrawal symptoms, operant ethanol self-administration under progressive ratio schedule, and cue-induced reinstatement of ethanol seeking in rats that had voluntarily consumed ethanol for at least 3 months before treatment. In addition, OSU-6162 blunted ethanol-induced dopamine output in nucleus accumbens of ethanol-naive rats [&lt;ulink linkID="1311572" linkType="Reference"&gt;1311572&lt;/ulink&gt;], [&lt;ulink linkID="1311738" linkType="Reference"&gt;1311738&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2000, data on &lt;ulink linkID="7837" linkType="Drug"&gt;PNU-96391A&lt;/ulink&gt; were presented at the 30th Neuroscience meeting in San Diego, CA. Infusion of &lt;ulink linkID="7837" linkType="Drug"&gt;PNU-96391A&lt;/ulink&gt; into the nigra produced slight decreases in ipsilateral striatal dopamine levels, compared to a 140 to 200% increase in striatal dopamine levels induced by a striatal infusion of &lt;ulink linkID="7837" linkType="Drug"&gt;PNU-96391A&lt;/ulink&gt; or &lt;ulink linkID="7837" linkType="Drug"&gt;PNU-96391A&lt;/ulink&gt; combined with &lt;ulink linkID="13534" linkType="Drug"&gt;raclopride&lt;/ulink&gt; [&lt;ulink linkID="390627" linkType="reference"&gt;390627&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The drug has antipsychotic-like effects as determined by estimates of dopamine synthesis, release and metabolism, but its behavioral effects in rodents differ from those of other antipsychotics. &lt;ulink linkID="7837" linkType="Drug"&gt;PNU-96391A&lt;/ulink&gt; inhibits D2 receptor function both in the nigra and the striatum. The effect of the drug in the nigra seems to be tone-dependent since it slightly reduces striatal dopamine levels when infused in the nigra but fully counteracts the reduction in striatal dopamine after nigral infusion of the D2 agonist 5-OH-DPAT [&lt;ulink linkID="346019" linkType="reference"&gt;346019&lt;/ulink&gt;]. The drug has similar effects to &lt;ulink linkID="13534" linkType="Drug"&gt;raclopride&lt;/ulink&gt; on striatal autoreceptors modulating dopamine release, and differential effects on nigral autoreceptors modulating impulse flow [&lt;ulink linkID="387742" linkType="reference"&gt;387742&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By September 1996, (-)-DS 121, an analog of &lt;ulink linkID="7837" linkType="Drug"&gt;PNU-96391A&lt;/ulink&gt; has been shown to increase local cerebral glucose utilization in several brain region and on the other hand to block the increases in local cerebral glucose utilization produced by 5 mg/kg iv cocaine [&lt;ulink linkID="281639" linkType="reference"&gt;281639&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><ExpertReview>&lt;para&gt;Dr Hasanah Che Ismail, Dept of Psychiatry, School of Medical Sciences, Universitit Sains Malaysia, Kelantan, Malaysia&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;24 July 1998&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;DS-121 belongs to a new class of dopamine (DA) receptor antagonists. It is a dopamine autoreceptor and D3 receptor antagonist undergoing developmental research at &lt;ulink linkType="Company" linkID="18995"&gt;Pharmacia &amp;amp; Upjohn&lt;/ulink&gt; as a potential treatment for depression, psychosis, schizophrenia and substance dependence.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;DS-121 was one of a series of substituted (S)-phenylpiperidines synthesized at the &lt;ulink linkType="Company" linkID="25752"&gt;University of Gothenburg&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="301821"&gt;301821&lt;/ulink&gt;]. Analogs with an aromatic substituent with a high group dipole moment in the 3-position, and N-substituted with a propyl group were highly active in vivo against the synthesis and turnover of dopamine.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;DS-121 is a dopamine autoreceptor-preferring antagonist. In vitro binding studies showed that DS-121 has about four-fold higher affinity for the dopamine D3 receptor compared to the dopamine D2 receptor. It also shows less than 50% inhibition at 1 microM of D1, D4, alpha1, alpha2, beta, 5-HT, 5-HT1D, 5-HT2, muscarinic, acetylcholine, benzodiazepine and opiate receptors [&lt;ulink linkType="reference" linkID="301821"&gt;301821&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;DS-121 is the most potent cocaine antagonist of three autoreceptor antagonists, that includes (+)-&lt;ulink linkType="Drug" linkID="13957"&gt;AJ-76&lt;/ulink&gt; (Astra Arcus) and (+)-&lt;ulink linkType="Drug" linkID="11890"&gt;UH-232&lt;/ulink&gt; (Astra). DS-121 also produces a more significant decrease in breaking point (BP) at 15 mg/kg, as well as significantly reducing rate of self-administration (SA) behaviour in rats [&lt;ulink linkType="reference" linkID="160528"&gt;160528&lt;/ulink&gt;]. At 7.0 to 14.0 mg/kg, it also weakly anatagonizes the cueing properties of both D-amphetamine and cocaine [&lt;ulink linkType="reference" linkID="262846"&gt;262846&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;These findings suggest that DS-121 shows cocaine antagonist effects without abuse potential, so that it may be useful for the treatment of cocaine abuse. This effect of DS-121 seemed to carry over to subsequent days of testing and often the experimental animals did not return to previous BP values on a progressive ratio (PR) schedule of reinforcement. This phenomenon suggests that DS-121 may have lasting effects on the reinforcing properties of cocaine [&lt;ulink linkType="reference" linkID="183328"&gt;183328&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;DS-121 (15 mg/kg ip) by itself, does not significantly alter metabolism in any brain region, but in combination with cocaine, DS-121 antagonizes the latter's stimulant effects on local cerebral glucose utilization (LCGU), particularly in cortical areas of rats. When combined with cocaine, DS-121 prolonged the cocaine-induced increase in extracellular striatal DA [&lt;ulink linkType="reference" linkID="262842"&gt;262842&lt;/ulink&gt;]. When rats were pretreated with DS-121 (15 mg/kg iv), a subsequent dose of cocaine (5 mg/kg iv) augmented the increase in extracellular striatal dopamine to 870% of controls. The results support the contention that DS-121 possesses weak cocaine-mimetic effects and that its antagonism of cocaine's subjective effects is due to inter-reactions with dopamine at postsynaptic sites. [&lt;ulink linkType="reference" linkID="244033"&gt;244033&lt;/ulink&gt;]. These cocaine-mimetic and cocaine antagonist properties may be beneficial in treating both cocaine craving and bingeing. Further investigation on the associative (possibly aversive) effect of pairing DS-121 with cocaine will be useful, as the comorbidity of schizophrenia and cocaine abuse is high.&lt;/para&gt;&lt;para&gt;DS-121 increases DA synthesis and metabolism over a wide dose range (3.1 to 400 micromol/kg sc). In the same dose range, DS-121 reverses the apomorphine-induced depression of DA synthesis in gamma-butyrolactone (GBL) treated rats. By itself, DS-121 has no effect on DA synthesis in GBL- or reserpine-pretreated rats. Thus DS-121 is an antagonist at the synthesis-regulating DA autoreceptors [&lt;ulink linkType="reference" linkID="160529"&gt;160529&lt;/ulink&gt;]. It also reverses apomorphine- and D-amphetamine-induced depression in substantia nigra and ventral tegmental area DA neurons. Such actions on DA autoreceptors have been used to explain its unusual behavioural effects [&lt;ulink linkType="reference" linkID="262844"&gt;262844&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Unlike typical DA antagonists, which produce sedation and catalepsy, DS-121 (25 to 200 micromol/kg sc) produces a mild (+50%) behavioural stimulation in actively exploring rats with no hypoactivity even after very high doses. The preference for the DA autoreptors of DS-121 is slightly higher than (+)-&lt;ulink linkType="Drug" linkID="13957"&gt;AJ-76&lt;/ulink&gt; and (+)-&lt;ulink linkType="Drug" linkID="11890"&gt;UH-232&lt;/ulink&gt;. This stimulant effect may be accounted for by its higher affinity for the D3 receptor. Some evidence suggests that the D3 receptor is inhibitory to locomotor activity, and that a D3 antagonist might produce a disinhibitory effect [&lt;ulink linkType="reference" linkID="160527"&gt;160527&lt;/ulink&gt;]. However, local bilateral infusion of DS-121 (0.05 to 53.0 microg/side) into the nucleus accumbens or ventral tegmental area did not produce locomotor stimulation. A weak but significant increase in locomotor activity was detected after bilateral infusion of DS-121 (66.3 microg/side) into the lateral ventricles. The same degree of locomotor activity as seen after systemic administration was not replicated with local application in either the terminal or somatodendritic regions of the mesolimbic pathway [&lt;ulink linkType="reference" linkID="262843"&gt;262843&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;DS-121 also produced conditioned place preference at 25 to 100 micromol/kg, sc. However, the stimulatory actions were not evident in intracranial self-stimulation experiments, where it in fact produced a non-significant tendency towards an increase in reward threshold in the dose range 3.5 to 50.0 micromol/kg sc. This is in contrast with (+)-&lt;ulink linkType="Drug" linkID="13957"&gt;AJ-76&lt;/ulink&gt; and (+)-&lt;ulink linkType="Drug" linkID="11890"&gt;UH-232&lt;/ulink&gt;, which produced a highly significant increase in reward threshold. It indicates that DS-121 has a stronger preference for the DA autoreceptor and it produces only weak, if any, positive reinforcement properties in the rat [&lt;ulink linkType="reference" linkID="160525"&gt;160525&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a later study by the same researchers, DS-121 induced conditioned place preference (CPP) in the dose range 3.3 to 13.3 mg/kg sc, as did D-amphetamine (0.25 to 4.0 mg/kg sc). However, in contrast to D-amphetamine, DS-121 failed to facilitate intracranial self-stimulation (ICSS) in the dose range that produced CPP [&lt;ulink linkType="reference" linkID="262843"&gt;262843&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;DS-121, in contrast to (+)-&lt;ulink linkType="Drug" linkID="13957"&gt;AJ-76&lt;/ulink&gt; and (+)-&lt;ulink linkType="Drug" linkID="11890"&gt;UH-232&lt;/ulink&gt;, does not depress 5-HT neuronal firing rates or block the depressant effect of 8-OH DPAT, suggesting that different autoreptor antagonists have different action on 5-HT cells that cannot be attributed to their similar effects on DA systems [&lt;ulink linkType="reference" linkID="160529"&gt;160529&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;No data are currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;No data are currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side-effects and Contraindications&lt;/subtitle&gt;No data are currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;D2 receptor blockade, traditionally the main target for conventional antipsychotics, has resulted in drugs with considerable neurotoxicity. Presently the recommendation for first-line treatment of psychoses are novel or atypical antipsychotics like &lt;ulink linkType="Drug" linkID="4236"&gt;risperidone&lt;/ulink&gt;. The development of DS-121 as an antipsychotic is a potential therapeutic breakthrough. Unlike typical DA antagonists, which produce sedation and catalepsy, this drug may in fact cause mild increases in locomotor activity. It is thus possibly superior to other established antipsychotics in treating schizophrenia with negative symptoms, as well as retarded psychotic depression.&lt;/para&gt;&lt;para&gt;The mild cocaine-mimetic effect of DS-121, as well as its antagonist properties, are most useful. Furthermore it is not positively reinforcing. This will make DS-121 a useful drug in the treatment of substance misuse and dependence, especially psychostimulants. Since there is a high prevalence of cocaine abuse and dependence in people undergoing treatment for schizophrenia, DS-121 may become the drug of choice in such circumstances. The use of DS-121 as a first-line antipsychotic may also prevent the risk of patients with schizophrenia from misusing psychostimulants.&lt;/para&gt;&lt;para&gt;D3 receptor-deficient mice showed significant behavioural change consistent with reduced anxiety, suggesting an anxiolytic-like effect of this D3 receptor mutation. This opens another avenue of study to discover the effect of DS-121 on anxious subject [&lt;ulink linkType="reference" linkID="301822"&gt;301822&lt;/ulink&gt;]. DS-121 is a promising compound for treatment of psychostimulants misuse and reducing the complication of cocaine use in schizophrenia. Clinical studies are needed to find out its effect on positive as well as negative symptoms in schizophrenia.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="21110">Karolinska Institutet</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="11">Alcoholism</Indication><StatusDate>2015-10-14T00:00:00.000Z</StatusDate><Source id="1703273" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25752">University of Gothenburg</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="11">Alcoholism</Indication><StatusDate>2015-10-14T00:00:00.000Z</StatusDate><Source id="1703273" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25752">University of Gothenburg</Company><Country id="NO">Norway</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="829">Fatigue</Indication><StatusDate>2017-09-05T00:00:00.000Z</StatusDate><Source id="1955107" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22006">Pharmacia &amp; Upjohn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="170">Huntingtons chorea</Indication><StatusDate>2002-03-11T00:00:00.000Z</StatusDate><Source id="444997" type="CONFERENCE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22006">Pharmacia &amp; Upjohn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="93">Depression</Indication><StatusDate>2002-03-11T00:00:00.000Z</StatusDate><Source id="444997" type="CONFERENCE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22006">Pharmacia &amp; Upjohn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="299">Schizophrenia</Indication><StatusDate>2002-03-11T00:00:00.000Z</StatusDate><Source id="444997" type="CONFERENCE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22006">Pharmacia &amp; Upjohn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="282">Psychotic disorder</Indication><StatusDate>2002-03-11T00:00:00.000Z</StatusDate><Source id="444997" type="CONFERENCE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22006">Pharmacia &amp; Upjohn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="588">Drug dependence</Indication><StatusDate>2002-03-11T00:00:00.000Z</StatusDate><Source id="444997" type="CONFERENCE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25752">University of Gothenburg</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="282">Psychotic disorder</Indication><StatusDate>2001-06-11T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25752">University of Gothenburg</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate>2001-06-11T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25752">University of Gothenburg</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="829">Fatigue</Indication><StatusDate>2014-01-27T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25752">University of Gothenburg</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2001-06-11T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25752">University of Gothenburg</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="588">Drug dependence</Indication><StatusDate>2001-06-11T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25752">University of Gothenburg</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="748">Injury</Indication><StatusDate>2014-01-27T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22006">Pharmacia &amp; Upjohn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="282">Psychotic disorder</Indication><StatusDate>1992-01-01T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22006">Pharmacia &amp; Upjohn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="588">Drug dependence</Indication><StatusDate>1992-01-01T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22006">Pharmacia &amp; Upjohn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate>1992-01-01T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22006">Pharmacia &amp; Upjohn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>1992-01-01T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21110">Karolinska Institutet</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="11">Alcoholism</Indication><StatusDate>2012-07-27T00:00:00.000Z</StatusDate><Source id="1311572" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25752">University of Gothenburg</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="11">Alcoholism</Indication><StatusDate>2012-07-27T00:00:00.000Z</StatusDate><Source id="1311572" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25752">University of Gothenburg</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="748">Injury</Indication><StatusDate>2012-07-27T00:00:00.000Z</StatusDate><Source id="1311572" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25752">University of Gothenburg</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="829">Fatigue</Indication><StatusDate>2012-07-27T00:00:00.000Z</StatusDate><Source id="1311572" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25752">University of Gothenburg</Company><Country id="NO">Norway</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="829">Fatigue</Indication><StatusDate>2017-06-28T00:00:00.000Z</StatusDate><Source id="1955107" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25752">University of Gothenburg</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="282">Psychotic disorder</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25752">University of Gothenburg</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="588">Drug dependence</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25752">University of Gothenburg</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="299">Schizophrenia</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25752">University of Gothenburg</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="93">Depression</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22006">Pharmacia &amp; Upjohn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate>1999-12-31T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22006">Pharmacia &amp; Upjohn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="282">Psychotic disorder</Indication><StatusDate>2001-06-01T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22006">Pharmacia &amp; Upjohn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="588">Drug dependence</Indication><StatusDate>2001-06-11T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22006">Pharmacia &amp; Upjohn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate>2001-06-11T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22006">Pharmacia &amp; Upjohn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2001-06-11T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20348">Teva Pharmaceutical Industries Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="1520">Narcolepsy</Indication><AwardedIndication>Treatment of narcolepsy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="8">Rejected</DesignationApplicationStatus><MileStoneDate>2016-12-02T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20348">Teva Pharmaceutical Industries Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="1520">Narcolepsy</Indication><AwardedIndication>Treatment of narcolepsy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="7">Negative Opinion</DesignationApplicationStatus><MileStoneDate>2016-07-13T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00630"><Name>Dopamine autoreceptor</Name><SwissprotNumbers/></Target><Target id="PTGT-00633"><Name>Dopamine D2 receptor</Name><SwissprotNumbers><Swissprot>O73810</Swissprot><Swissprot>P14416</Swissprot><Swissprot>P20288</Swissprot><Swissprot>P52702</Swissprot><Swissprot>P60026</Swissprot><Swissprot>P61168</Swissprot><Swissprot>P61169</Swissprot><Swissprot>Q9GJU1</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00634"><Name>Dopamine D3 receptor</Name><SwissprotNumbers><Swissprot>P19020</Swissprot><Swissprot>P30728</Swissprot><Swissprot>P35462</Swissprot><Swissprot>P52703</Swissprot><Swissprot>Q5IS72</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1047641">Swedish Research Council</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1074381">The Swedish National Board of Health and Welfare</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1074415">Swedish Brain Foundation</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1074440">Eva and Oscar Ahréns Foundation</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1074443">Olle Engkvist Foundation</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1074446">Systembolaget</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="21110">Karolinska Institutet</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>7</CountTotal></Company><Company><Company id="25752">University of Gothenburg</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>6</CountActive><CountInactive>0</CountInactive><CountTotal>6</CountTotal></Type><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CCCN1CCC[C@H](C1)c2cccc(c2)S(=O)(=O)C</Smiles><Smiles>CCCN1CCC[C@H](C1)c2cccc(c2)C#N</Smiles></StructureSmiles><Deals><Deal id="142312" title="University of Gothenburg and Karolinska Institute to collaborate for development of OSU-6162 against alcohol dependence"/><Deal id="142313" title="Swedish Research Council to award Karolinska Institute funding for development of OSU-6162 against alcohol dependence"/><Deal id="142320" title="National Board of Health and Welfare to award Karolinska Institute funding for development of OSU-6162 against alcohol dependence"/><Deal id="142338" title="Swedish Brain Foundation to award Karolinska Institute funding for development of OSU-6162 against alcohol dependence"/><Deal id="142360" title="Eva and Oscar Ahréns Foundation to award Karolinska Institute funding for development of OSU-6162 against alcohol dependence"/><Deal id="142362" title="Olle Engkvist Foundation to award Karolinska Institute funding for development of OSU-6162 against alcohol dependence"/><Deal id="142363" title="Swedish Alcohol Retailing Monopoly to award Karolinska Institute funding for development of OSU-6162 against alcohol dependence"/></Deals><PatentFamilies><PatentFamily id="2102974" number="WO-2004039779" title="Process for the preparation of pyridyl-aryl-sulphonic compounds"/><PatentFamily id="3444467" number="WO-2016180879" title="Treatment of debilitating fatigue"/><PatentFamily id="356516" number="WO-2008155357" title="Use of dopamine stabilizers"/><PatentFamily id="600974" number="WO-2012039660" title="Phenylpiperidine compounds for the treatment of neurological and psychiatric disorders"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="NeuroSearch A/S" id="18504"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>